MX2016015632A - Compuestos heteroaromaticos espirociclicos, fusionados para el tratamiento de infecciones bacterianas. - Google Patents

Compuestos heteroaromaticos espirociclicos, fusionados para el tratamiento de infecciones bacterianas.

Info

Publication number
MX2016015632A
MX2016015632A MX2016015632A MX2016015632A MX2016015632A MX 2016015632 A MX2016015632 A MX 2016015632A MX 2016015632 A MX2016015632 A MX 2016015632A MX 2016015632 A MX2016015632 A MX 2016015632A MX 2016015632 A MX2016015632 A MX 2016015632A
Authority
MX
Mexico
Prior art keywords
bacterial infections
fused
treatment
heteroaromatic compounds
spirocyclic
Prior art date
Application number
MX2016015632A
Other languages
English (en)
Other versions
MX365261B (es
Inventor
Huband Michael
Original Assignee
Entasis Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entasis Therapeutics Ltd filed Critical Entasis Therapeutics Ltd
Publication of MX2016015632A publication Critical patent/MX2016015632A/es
Publication of MX365261B publication Critical patent/MX365261B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se divulgan métodos para tratar diversas infecciones bacterianas con (2R,4S,4aS)-11-fluoro-2,4-dimetil-8-[(4S)-4-metil-2-oxo-1,3-ox azolidin-3-il]-1,2,4,4a-tetrahidro-2´H,6H-espiro[1,4-oxazino[4,3- a][1,2]oxazolo[4,5-g]quinolin-5,5'-pirimidin]-2',4´,6´(1´H,3´H)-t riona, o una de sus sales farmacéuticamente aceptables.
MX2016015632A 2014-05-29 2015-05-27 Compuestos heteroaromaticos espirociclicos, fusionados para el tratamiento de infecciones bacterianas. MX365261B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462004246P 2014-05-29 2014-05-29
PCT/IB2015/001585 WO2015181637A1 (en) 2014-05-29 2015-05-27 Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections

Publications (2)

Publication Number Publication Date
MX2016015632A true MX2016015632A (es) 2017-04-25
MX365261B MX365261B (es) 2019-05-27

Family

ID=54329851

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015632A MX365261B (es) 2014-05-29 2015-05-27 Compuestos heteroaromaticos espirociclicos, fusionados para el tratamiento de infecciones bacterianas.

Country Status (14)

Country Link
US (1) US10238661B2 (es)
EP (1) EP3148546A1 (es)
JP (1) JP6502387B6 (es)
KR (1) KR20170007818A (es)
CN (1) CN106659725A (es)
AU (1) AU2015265620B2 (es)
CA (1) CA2948438A1 (es)
EA (1) EA033459B1 (es)
IL (1) IL248838B (es)
MX (1) MX365261B (es)
PH (1) PH12016502271B1 (es)
SG (2) SG11201609404SA (es)
TW (1) TWI657818B (es)
WO (1) WO2015181637A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109111465B (zh) * 2017-06-22 2021-01-12 中国科学院上海药物研究所 噻唑烷酮螺嘧啶三酮类化合物及制备方法和用途
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208490B2 (en) 2002-10-07 2007-04-24 Pharmacia & Upjohn Company Llc Tricyclic tetrahydroquinoline antibacterial agents
EP1664052B1 (en) 2003-08-15 2009-02-18 AstraZeneca AB Fused heterocycles as inhibitors of glutamate racemase (muri)
JP2008543739A (ja) 2005-05-09 2008-12-04 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 抗菌剤
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CL2007003332A1 (es) 2006-11-24 2008-06-20 Actelion Pharmaceuticals Ltd Compuestos derivados de heterociclos condensados; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o tratamiento de infecciones bacterianas.
CA2691485A1 (en) 2007-07-02 2009-01-08 Astrazeneca Ab Chemical compounds
BRPI0920180B1 (pt) 2008-10-14 2021-10-26 Entasis Therapeutics Limited Compostos herecíclicos substituídos, uso dos mesmos e composiçâo farmacêutica compreendendo os ditos compostos
US9040528B2 (en) 2008-10-14 2015-05-26 Astrazeneca Ab Chemical compounds 542
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US8952149B2 (en) 2012-09-26 2015-02-10 Zoetis Llc Tricyclic tetrahydroquinoline antibacterial agents
US8889671B2 (en) 2013-01-23 2014-11-18 Astrazeneca Ab Compounds and methods for treating bacterial infections

Also Published As

Publication number Publication date
CN106659725A (zh) 2017-05-10
SG10201906842WA (en) 2019-08-27
IL248838B (en) 2020-05-31
TWI657818B (zh) 2019-05-01
JP2017516777A (ja) 2017-06-22
PH12016502271A1 (en) 2017-02-06
US10238661B2 (en) 2019-03-26
PH12016502271B1 (en) 2017-02-06
WO2015181637A1 (en) 2015-12-03
TW201607537A (zh) 2016-03-01
SG11201609404SA (en) 2016-12-29
US20180169104A1 (en) 2018-06-21
AU2015265620A1 (en) 2016-11-24
AU2015265620B2 (en) 2020-04-09
EP3148546A1 (en) 2017-04-05
IL248838A0 (en) 2017-01-31
KR20170007818A (ko) 2017-01-20
JP6502387B2 (ja) 2019-04-17
EA201692250A1 (ru) 2017-06-30
EA033459B1 (ru) 2019-10-31
MX365261B (es) 2019-05-27
CA2948438A1 (en) 2015-12-03
JP6502387B6 (ja) 2019-05-29

Similar Documents

Publication Publication Date Title
IL251285B (en) 3-substituted 5-amino-h6-triazolo[5,4-d]pyrimidine-7,2-dione compounds for the treatment and prevention of virus infection
PL3838274T3 (pl) Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
EP4338739A3 (en) Diaryl macrocycles as modulators of protein kinases
LT3183254T (lt) Naujieji spiro[3h-indol-3,2' -pirolidin]-2(1h)-ono junginiai ir dariniai, kaip mdm2-p53 inhibitoriai
NZ763737A (en) 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
PH12019501079A1 (en) Magl inhibitors
PH12016502307B1 (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
MX2016015762A (es) Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaspiro undecano que tienen actividad multimodal contra el dolor.
MX2016015761A (es) Derivados de amina de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor.
ZA201700110B (en) Compounds comprising 1,1',2,5'-tetrahydrospiro[indole-3,2'-pyrrole]-2,5'-dione system as inhibitors p53-mdm2 protein-protein interaction
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2018002033A (es) Agentes antibacterianos que comprenden una pirazino[2,3-b] [1,4]oxazin-3-ona o un sistema de anillo relacionado.
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,.
PH12016502271A1 (en) Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
CL2016001024A1 (es) Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades.
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
EA201390620A1 (ru) ОКСАЗОЛО[5,4-b]ПИРИДИН-5-ИЛЬНЫЕ СОЕДИНЕНИЯ
BR112018016208A2 (pt) compostos heterocíclicos, em particular derivados 2-oxo-4,4,5,5,6,6,7,7-octahidrobenzoxazol, e seus usos como compostos antibacterianos

Legal Events

Date Code Title Description
FG Grant or registration